Nuwellis, Inc. (NUWE) stock
Close on Nov 11, 2026Market cap $3.18MP/E –Yield –
Nuwellis, Inc. grew revenue 8.4% to $9.01M over the twelve months to Jun 30, 2026. Free cash flow was -$12.59M. At the latest close the market valued the company at $3.18M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.18M
- P/E ratio
- –
- Price to sales
- 0.35
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -396.29%
Fundamentals
- Revenue
- $9.01M
- Net income
- -$11.32M
- EPS, diluted
- -$888.65
- Free cash flow
- -$12.59M
- Book value per share
- -$11.34
- Diluted shares
- 0M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $5.24
- Open
- $5.24
- Day's range
- $5.24 – $5.74
- Volume
- 39,981
- Average volume (20 days)
- 2,116,841
- 52-week range
- $2.52 – $1556.16
- RSI (14 days)
- 49.0
- Volatility (1 year)
- 227.7%
- Relative volume
- 0.05×
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NUWE | S&P 500 | Difference | NUWE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.8% | -2.4% | −8.4 pts | ||
| 3 months | -58.5% | -1.2% | −57.3 pts | ||
| Year to date | -99.0% | +12.3% | −111.3 pts | ||
| 1 year | -99.4% | +12.4% | −111.8 pts | ||
| 3 years | -99.9% | +78.8% | −178.7 pts | -91.2% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.1 pts | -81.2% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -88.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nuwellis filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- News
- Update
- Update
- Results
About Nuwellis
Electromedical & Electrotherapeutic Apparatus
Nuwellis, Inc. is a medical technology company dedicated to advancing cardiorenal care through specialized fluid management solutions. The company develops, manufactures, and commercializes medical devices designed for ultrafiltration therapy, primarily the Aquadex SmartFlow and Aquadex FlexFlow systems. These devices remove excess fluid and salt from patients experiencing hypervolemia or fluid overload who have proven unresponsive to conventional medical treatments, such as diuretics. Nuwellis focuses its commercial offerings on three primary clinical sectors: pediatrics, critical care, and heart failure.
Company profile, executives and historyNuwellis stock: common questions
What is Nuwellis's stock price?
NUWE closed at $5.53 on Nov 11, 2026, up 5.53% on the day. Over the past 52 weeks it traded between $2.52 and $1556.16.
What is Nuwellis's market cap?
Nuwellis was worth $3.18M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NUWE's P/E ratio?
Nuwellis lost money over fiscal 2025 (diluted EPS -$888.65), so it has no meaningful P/E ratio.
How much revenue does Nuwellis make?
Nuwellis reported revenue of $9.01M for the twelve months to Jun 30, 2026, up 8.4% from a year earlier.
Does Nuwellis pay a dividend?
No. Nuwellis has not paid a cash dividend over the last twelve months.
When does Nuwellis report earnings next?
Nuwellis is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NUWE stock performed over the past year?
Including dividends, NUWE returned -99.4% over the past year, against +12.4% for the S&P 500.
Who are Nuwellis's competitors?
Companies most similar to Nuwellis by business, industry and size include NRXS, NMTC, EBRCZ, ELMD, CV.
See a number that looks wrong?